Singapore markets close in 7 hours 52 minutes

Novo Nordisk A/S (NVO)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
128.64+3.38 (+2.70%)
At close: 04:00PM EDT
128.99 +0.35 (+0.27%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close125.26
Open126.57
Bid128.60 x 2200
Ask129.00 x 1000
Day's range126.34 - 128.76
52-week range75.56 - 138.28
Volume3,700,021
Avg. volume5,017,583
Market cap573.931B
Beta (5Y monthly)0.19
PE ratio (TTM)48.36
EPS (TTM)2.66
Earnings dateN/A
Forward dividend & yield1.37 (1.10%)
Ex-dividend date22 Mar 2024
1y target est144.64
  • Zacks

    Novo Nordisk (NVO) Boasts Earnings & Price Momentum: Should You Buy?

    Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.

  • GlobeNewswire

    Novo Nordisk A/S - share repurchase programme

    Bagsværd, Denmark, 22 April 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme i

  • Yahoo Finance Video

    Weight loss drugs and the many use cases in medical treatments

    Novo Nordisk's (NVO) Ozempic and Wegouvy and Eli Lilly's (LLY) Zepbound are the leading names in the latest GLP-1 weight loss drug cycle, a trend that has seen a variety of use cases sprout up since these brand names' inceptions late last year. Yahoo Finance Health Reporter Anjalee Khemlani explains the new use cases being found for this class of drugs, including infertility treatments and even benefits for Alzheimer's patients. For more expert insight and the latest market action, click here to watch this full episode. This post was written by Luke Carberry Mogan.